3-(1-Hydroxy-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-(1-Hydroxy-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione
• 英文别名: 3-(1-hydroxy-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione
• 化学式: C₁₃H₁₄N₂O₃
• 分子量: 246.26
• InChiKey: AIXRQGMMHMJZGE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  69.6
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] BCL-2 INHIBITORS<br/>[FR] INHIBITEURS DE BCL-2
  申请人：NEWAVE PHARMACEUTICAL INC

  公开号：WO2020041406A1

  公开（公告）日：2020-02-27

  The disclosure includes compounds of Formula (A), (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1, Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.
• [EN] CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS<br/>[FR] HÉTÉROCYCLES CONDENSÉS EN TANT QU'INHIBITEURS DE BCL-2
  申请人：NEWAVE PHARMACEUTICAL INC

  公开号：WO2021066873A1

  公开（公告）日：2021-04-08

  The disclosure includes compounds of Formula (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1 Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.